Last edition
News about "HRS-1893"
Hengrui Pharma Grants Braveheart Bio Exclusive Global Rights to Cardiac Myosin Inhibitor HRS-1893
Hengrui Pharma has signed an exclusive licensing deal with US-based Braveheart Bio for its Phase 3-ready cardiac myosin inhibitor HRS-1893. Braveheart will make an upfront payment of USD 65 million and a near-term payment of up to USD 10 million upon technology transfer completion, totalling USD 75 million.
HRS-1893 | 06/09/2025 | By Mrinmoy Dey | 194
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members